20-Bio-A1 Biomaterials and Biocompatibility · December 2016
Nivaar worked solution (AI-drafted; not reviewed by a licensed engineer)
Paper format: National Exams, December 2016 — 04-Bio-A1 Biomaterials and Biocompatibility. Three hours, open book, any non-communicating calculator. Six questions of equal value (20 marks each, 100 marks total for a complete paper); five constitute a complete exam paper and only the first five appearing in the answer book are marked. All six are solved here, because this set is a study resource rather than an examination script. Most questions require an essay-format answer (materials selection, host response, surface/mechanical characterization); Question 6 additionally asks for an engineering interpretation of a small stress–strain data set, so it quotes and reasons from descriptive statistics computed from the given numbers while still answering in the flowing prose the question calls for.
Reference texts (the books an open-book candidate should have on the desk for this subject):
Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.
An "off the shelf" whole-organ heart replacement, starting from embryonic stem cells (ESCs) alone, requires work across at least seven linked technical areas, and the single line of technical information given (cell source only) is nowhere near sufficient to validate the claim. Cell-source biology and differentiation comes first: ESCs must be reproducibly directed down a cardiomyocyte lineage (and, for a functional organ, also into the supporting vascular endothelial, smooth-muscle, and cardiac-conduction-system cell types) at high purity, because any residual undifferentiated pluripotent cells carry a real tumorigenic (teratoma) risk once implanted. Scaffold/matrix engineering provides the 3-D architecture the cells are seeded onto or into — either a decellularized native heart extracellular matrix (which retains the organ's vascular tree and fibre architecture) or a synthetic/hybrid biomaterial scaffold engineered to match the heart wall's anisotropic mechanical properties (it must stretch and recoil cyclically, hundreds of millions of times over a lifetime, without fatigue failure) and its electrical conduction pathways. Vascularization and perfusion engineering is a hard, still largely unsolved problem for whole-organ scale tissue: diffusion alone only sustains viable tissue to roughly 100–200 µm from a capillary, so a functioning heart of clinically useful size needs an engineered, perfusable microvascular network established before or during cell seeding, not just a bulk scaffold. Electromechanical functional integration must give synchronized, coordinated contraction (via functional gap junctions and a conduction pathway analogous to the native SA/AV node and Purkinje system) rather than disorganized, arrhythmia-prone twitching of isolated cardiomyocyte patches. Immunogenicity management is essential because ESC-derived tissue is allogeneic (or, if from a third-party donor line, fully foreign) to the eventual recipient, so either lifelong immunosuppression, genetic immune-evasion engineering of the donor cell line, or a patient-matched/induced-pluripotent-cell approach must be part of the technology. Manufacturing, bioreactor, and quality-system scale-up is needed to reproducibly grow a viable, GMP-quality whole organ (very different from a benchtop proof-of-concept), and regulatory and long-term preclinical validation (large-animal survival studies, a defined combination-product regulatory pathway, and an ISO 10993/quality-system framework) closes the loop from laboratory demonstration to an actual "off the shelf" clinical product.
Given only "cell source: embryonic stem cells," the economic team should be told that success has to be judged against criteria spanning function, durability, safety, and manufacturability — not against the marketing claim alone. Functional criteria: demonstrated adequate cardiac output/ejection fraction and stable, synchronized (non-arrhythmic) contraction in a physiologically relevant large-animal orthotopic transplant model, sustained over a clinically meaningful period, not just a benchtop contraction assay. Structural/durability criteria: long-term mechanical integrity of the scaffold and tissue under continuous cyclic loading (no aneurysmal dilation, no scaffold degradation-driven wall thinning) and a demonstrated, maintained microvascular perfusion over time. Biocompatibility and safety criteria: no teratoma formation from residual undifferentiated ESCs, no clinically significant rejection response, and no thromboembolic events from any blood-contacting engineered surface (directly analogous to the vascular-graft haemocompatibility problem of Question 3). Manufacturability/reproducibility criteria: consistent product quality and functional performance across independently manufactured units, since a device claimed to be "off the shelf" implies a reproducible manufacturing process, not a one-off laboratory success. Regulatory/translational criteria: a credible, de-risked path through the applicable combination-product regulatory framework with a completed preclinical safety/efficacy package. A firm that can show only isolated cardiomyocyte contraction in a dish, with no vascularization, immunogenicity, or large-animal durability data, has not demonstrated a viable "heart" by any of these criteria, regardless of how the technology is described in a stock-price-oriented communication.
A due-diligence checklist built from these criteria — e.g., "cardiomyocyte purity and residual-pluripotency assay: UNKNOWN, HIGH risk; engineered microvascular perfusion demonstrated in vivo: UNKNOWN, HIGH risk; large-animal survival >90 days: UNKNOWN, HIGH risk".
